Array BioPharma to present data on ARRY-520 Phase 1 trial for multiple myeloma at ASH Annual Meeting

Download PDF Copy

Editorial Checklist

Reviewed

Array BioPharma Inc.Nov 30 2010

NewsGuard 100/100 Score

Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will present data from a Phase 1 trial of KSP inhibitor ARRY-520 in patients with relapsed/refractory multiple myeloma at the 2010 Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on Saturday, December 4, 2010.

The abstract can be accessed through the ASH website, www.hematology.org/Meetings/Annual-Meeting. The abstract title is provided below, however, please note that according to ASH policy, all data is embargoed until the time of the beginning of the presentation. The poster will be available as a PDF after it is presented on Array's website at www.arraybiopharma.com.

Source:

Array BioPharma Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: Cancer, Hematology, Multiple Myeloma, Myeloma

Comments (0)

Download PDF Copy

Suggested Reading

Weill Cornell Medicine secures $12.4 million grant for lymphoma research

Weill Cornell Medicine secures $12.4 million grant for lymphoma research

Outpatient CAR-T therapy shows promise for treating lymphoma patients

Outpatient CAR-T therapy shows promise for treating lymphoma patients

Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers

Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers

Cancer drug shows promise for treating rare bleeding disorder

Cancer drug shows promise for treating rare bleeding disorder

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

Stroke risk rises in patients with sickle cell disease despite established guidelines

Stroke risk rises in patients with sickle cell disease despite established guidelines

Study uncovers how OTX2 drives aggressive childhood brain cancer

Study uncovers how OTX2 drives aggressive childhood brain cancer

Brazil-Italy joint lab focuses on Alzheimer’s drug development

Brazil-Italy joint lab focuses on Alzheimer’s drug development

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New discovery offers hope for overcoming CAR-T cell therapy resistance